Key Factors to Consider When Selecting a Pancreatin Pellets Manufacturer

The single most important quality attribute of any pancreatin product is retained enzyme activity — measured in lipase, amylase, and protease units — through manufacturing, coating, storage, and shelf life. Pancreatin enzymes are proteins, and proteins are inherently sensitive to heat, moisture, and mechanical stress. A competent manufacturer must demonstrate:

• Process temperatures kept within tightly controlled, low ranges during granulation, drying, and coating to avoid enzyme denaturation.
• Validated enzyme assay methods (typically pharmacopoeial methods per USP, Ph. Eur., or IP) with documented activity data at release and throughout stability studies.
• A track record of consistent activity retention across multiple production batches, not just a single successful lot.

Ask for real stability data, ideally covering the full proposed shelf life under both accelerated and long-term storage conditions, and confirm the enzyme units per pellet remain within specification through that entire period.

Pancreatin enzymes are destroyed by gastric acid, so pancreatin pellets must be enteric-coated to survive passage through the stomach and release their enzyme content in the more neutral pH environment of the small intestine. This makes enteric coating expertise a non-negotiable capability. Evaluate the manufacturer on:

• The specific enteric polymer systems used (commonly methacrylic acid copolymers or similar pH-triggered systems) and their proven dissolution behavior at gastric versus intestinal pH.
• Coating uniformity across the pellet population, since under-coated pellets risk premature enzyme release and destruction, while over-coated pellets may delay release beyond the optimal absorption window.
• Data demonstrating acid resistance (typically less than 10% drug release after two hours in simulated gastric fluid) alongside rapid release in intestinal-simulated conditions.

Clinical guidelines and regulatory expectations increasingly favor smaller pancreatin pellets (often under 2mm) to ensure even gastric emptying alongside food and more uniform distribution of enzyme activity throughout the intestine. A manufacturer’s ability to consistently produce fine, uniformly sized micro-pellets — rather than larger, less physiologically optimal granules — is a meaningful differentiator. Ask about:

• Achievable pellet size ranges and the technology used (extrusion-spheronization versus fluid-bed layering).
• Particle size distribution control and the associated in-process testing regime.
• Any clinical or biopharmaceutical rationale the manufacturer can offer for their chosen pellet size range.

Because pancreatin is an animal-derived material, sourcing and traceability carry additional regulatory weight. A quality manufacturer should be able to provide:

• Documentation on the source animal species, geographic origin, and TSE/BSE (transmissible spongiogenic encephalopathy) risk certification.
• Supplier qualification records for the crude pancreatin raw material, including activity specifications at the point of receipt.
• A robust incoming raw material testing program, since crude pancreatin can vary significantly in baseline enzyme activity from batch to batch, requiring standardization before formulation.

Pancreatin products, given their biological origin and therapeutic seriousness, are subject to close regulatory scrutiny. Check for:

• WHO-GMP, EU-GMP, or other relevant certifications specific to the facility producing the pellets.
• An existing Drug Master File or willingness to support one, including full analytical and stability data packages.
• A clean regulatory inspection history, with particular attention to any observations related to bioburden control, since pancreatin’s animal origin and enzymatic nature make microbial control a key quality concern.

Because pancreatin is derived from animal tissue and is enzymatically active (rather than sterilized through terminal processes typical of small molecules), microbial control throughout manufacturing is critical. Ask the manufacturer to detail:

• Bioburden limits applied at each stage of processing, from raw material receipt through to finished pellets.
• Environmental monitoring programs in manufacturing areas.
• Validated cleaning and sanitization procedures for equipment that comes into contact with the enzyme material.